Roivant Sciences Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.0%projected annual EPS growth
Analyst Coverage
11analysts covering
FY EPS (est.)
-$1.58next fiscal year
Monitoring Framework
Key Performance Indicators
Consolidated Cash, Cash Equivalents, and Marketable Securities Quarterly4.3BTarget: Sufficient liquidity to support cash runway into profitability
IMVT-1402 Rheumatoid Arthritis ACR20 Response Rate (Week 16) Quarterly72.7%Target: Demonstrate clinically meaningful efficacy in difficult-to-treat RA
Watch Items
- FDA PDUFA Target Action Date for Brepocitinib in DermatomyositisTrigger: Brepocitinib NDA approval or Phase 3 topline data readouts in 2H 2026Action: Re-evaluate valuation model and revenue projections upon publication of Phase 3 results or regulatory decision
- Moderna Patent Litigation Settlement Upfront PaymentTrigger: $950 million cash inflow expected in July 2026Action: Allocate capital toward pipeline development and execute authorized share buybacks
- Topline Phase 2 Data for Mosliciguat in PH-ILDTrigger: Second Half of Calendar Year 2026Action: Evaluate efficacy signals (PVR reduction) and plan registrational pathways
Research as of 2 Sep 2026